Valuation: Novartis AG

Market Cap 287B 248B 233B 212B 398B 27,419B 404B 2,727B 1,066B 13,731B 1,077B 1,053B 45,629B P/E 2026 *
21.4x
P/E 2027 * 18.3x
Enterprise Value 320B 276B 260B 236B 444B 30,585B 451B 3,042B 1,189B 15,316B 1,201B 1,175B 50,898B EV / Sales 2026 *
5.54x
EV / Sales 2027 * 5.14x
Free-Float
91.66%
Yield 2026 *
2.89%
Yield 2027 * 3.02%
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Compliance Officer 58 2025-04-13
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-0.77% - - 287B
-0.42%-0.47%+68.30%+116.05% 1,052B
-0.42%+0.43%+47.39%+51.02% 627B
-0.25%+1.39%+20.69%+64.61% 441B
-0.11%-4.61%+39.02%+37.97% 349B
-0.27%-3.19%+22.49%+36.61% 287B
+0.33%-3.59%-1.52%+7.12% 241B
-0.61%+1.04%+40.05%+56.67% 224B
-1.48%-4.44%-15.81%-54.10% 202B
-0.69%+3.87%+16.89%+77.38% 172B
Average -0.25%-0.77%+26.39%+43.70% 399.46B
Weighted average by Cap. -0.23%-0.63%+38.70%+62.06%

Financials

2026 *2027 *
Net sales 57.71B 49.84B 46.83B 42.59B 80.08B 5,518B 81.4B 549B 215B 2,763B 217B 212B 9,182B 61.25B 52.9B 49.71B 45.21B 85B 5,857B 86.4B 583B 228B 2,933B 230B 225B 9,747B
Net income 13.95B 12.05B 11.32B 10.3B 19.36B 1,334B 19.68B 133B 51.87B 668B 52.38B 51.24B 2,220B 15.5B 13.39B 12.58B 11.44B 21.51B 1,482B 21.87B 147B 57.64B 742B 58.2B 56.94B 2,467B
Net Debt 33.11B 28.6B 26.88B 24.44B 45.95B 3,166B 46.71B 315B 123B 1,586B 124B 122B 5,269B 27.82B 24.03B 22.58B 20.53B 38.6B 2,660B 39.24B 265B 103B 1,332B 104B 102B 4,426B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
150.86USD
Average target price
154.18USD
Spread / Average Target
+2.20%

Quarterly revenue - Rate of surprise